| Literature DB >> 32328547 |
Usman Khan1, Michael Abunassar2,3, Avijit Chatterjee3, Paul D James4.
Abstract
BACKGROUND: The quality of endoscopic ultrasound (EUS) involving advanced endoscopy trainees (AETs) is not well understood. In this study, we aimed to examine adverse events (AE) risk and diagnostic yield of EUS procedures involving AETs.Entities:
Year: 2018 PMID: 32328547 PMCID: PMC7165263 DOI: 10.1093/jcag/gwy066
Source DB: PubMed Journal: J Can Assoc Gastroenterol ISSN: 2515-2084
Figure 1.Flow diagram of included and excluded cases.
Baseline characteristics of patients who underwent endoscopic ultrasound
| Variable | Trainee Absent |
|
| |
|---|---|---|---|---|
| Age in years, median (IQR) | 63 (54–73) | 64 (52–73) | 0.48 | |
| Male sex | 592 (49) | 237 (52) | 0.21 | |
| Smoker | 419 (35) | 137 (30) | 0.06 | |
| Charlson Comorbidity Index | 3 (1–4) | 3 (1–4) | 0.81 | |
| EUS indication | <0.01 | |||
| Abdominal pain | 68 (5.6) | 13 (2.9) | ||
| Abnormal lymph node(s) | 42 (3.5) | 20 (4.4) | ||
| Duodenal tumor | 23 (1.9) | 8 (1.8) | ||
| Esophageal cancer staging | 30 (2.5) | 6 (1.3) | ||
| Esophageal tumor | 30 (2.5) | 5 (1.1) | ||
| Gallstone disease | 48 (4.0) | 10 (2.2) | ||
| Gastric cancer staging | 27 (2.2) | 9 (2.0) | ||
| Gastric tumor | 91 (7.5) | 36 (8.0) | ||
| Pancreatic cystic lesion | 148 (12) | 50 (11) | ||
| Pancreatic solid tumor | 274 (23) | 144 (32) | ||
| Pancreatitis | 115 (9.5) | 35 (7.8) | ||
| Rectal cancer staging | 20 (1.7) | 10 (2.2) | ||
| Subepithelial lesion | 61 (5.0) | 41 (9.1) | ||
| Other | 241 (20) | 73 (16) | ||
|
| ||||
| Anesthesia-guided sedation | 44 (4) | 34 (8) | <0.01 | |
| Cytotechnologist present | 431 (36) | 168 (37) | 0.57 | |
| Upper EUS | 1169 (97) | 434 (96) | 0.53 | |
| Type of endoscope used | <0.01 | |||
| Linear | 851 (72) | 375 (84) | ||
| Radial | 225 (19) | 64 (14) | ||
| Linear and radial | 111 (9) | 10 (2) | ||
| Additional procedure performed on same day as EUS | <0.01 | |||
| Gastroscopy | 150 (12) | 28 (6) | ||
| Colonoscopy | 17 (1) | 7 (2) | ||
| Flexible sigmoidoscopy | 10 (1) | 4 (1) | ||
| ERCP | 49 (4) | 40 (9) | ||
|
| ||||
| FNA performed | 651 (54) | 279 (62) | <0.01 | |
| Number of FNA passes, median (IQR) | 3 (3–4) | 3 (3–4) | 0.16 | |
| FNA needle gauge‡ | 25 g | 50 (8) | 9 (3) | <0.01 |
| 22 g | 502 (78) | 244 (86) | <0.01 | |
| 19 g | 85 (13) | 29 (10) | 0.19 | |
| FNA approach‡ | Transesophageal | 55 (9) | 6 (2) | <0.01 |
| Transgastric | 249 (41) | 114 (46) | 0.14 | |
| Transduodenal | 291 (48) | 120 (49) | 0.79 | |
| Lesion size (≥ 3 cm) | 206 (36) | 125 (51) | <0.01 | |
| Type of lesion | 0.20 | |||
| Predominantly cystic | 119 (28) | 38 (20) | ||
| Predominantly solid | 194 (45) | 88 (47) | ||
| Solid and cystic | 44 (10) | 24 (13) | ||
| Other | 74 (17) | 39 (21) | ||
Unless otherwise indicated.
†Limited to EUS-FNA procedures only.
‡Global P value < 0.01.
Adverse events risk within 30 days of endoscopic ultrasound, relation to the procedure, and outcomes
| Variable |
|
|
|
|---|---|---|---|
| Emergency room visit or hospitalization | 64 (5) | 39 (9) | 0.01 |
| Relation to EUS procedure | 0.69 | ||
| Definitely-related | 18 (2) | 14 (3) | |
| Possibly-related | 16 (1) | 8 (2) | |
| Not-related | 30 (2) | 17 (4) | |
|
| |||
| Number of adverse events | 34 (3) | 22 (5) | 0.04 |
| Number requiring hospitalization | 18 (2) | 9 (2) | 0.47 |
| Median number of days in hospital (IQR) | 6 (3–15) | 4 (2–13) | 0.23 |
| Number requiring ICU care | 3 (0.2) | 4 (1) | 0.09 |
|
| |||
| Antibiotics | 11 (1) | 5 (1) | 0.78 |
| Blood transfusion (units) | 1 (0.1) | 2 (0.4) | 0.18 |
| Endoscopic management | 1 (0.1) | 1 (0.2) | 0.47 |
| Surgical management | 2 (0.2) | 2 (0.4) | 0.30 |
|
| |||
| Infection | 3 (0.3) | 3 (1) | |
| Gastrointestinal bleeding | 2 (0.2) | 1 (0.2) | 1.00 |
| Pancreatitis | 6 (1) | 3 (1) | 0.71 |
| Perforation | 0 | 2 (0.4) | 0.64 |
| Pulmonary embolism | 1 (0.2) | 0 | 1.00 |
Unless otherwise indicated.
†Cases that were definitely- and possibly-related to the EUS procedure were included.
ICU: intensive care unit
Endoscopic ultrasound related adverse event risk and diagnostic yield over a one-year advanced endoscopy training period*
| Training Quartile‡ | Adverse Event Risk | Diagnostic Yield† | ||||||
|---|---|---|---|---|---|---|---|---|
| n |
|
|
|
|
|
|
| |
| 1 | 433 | 9 (3) | 8 (8) | 0.04 | 243 | 128 (72) | 42 (76) | 0.55 |
| 2 | 352 | 5 (2) | 0 | 0.59 | 185 | 106 (78) | 44 (90) | 0.07 |
| 3 | 412 | 11 (4) | 6 (4) | 1.00 | 250 | 120 (78) | 63 (75) | 0.61 |
| 4 | 458 | 9 (3) | 8 (6) | 0.11 | 252 | 119 (73) | 62 (77) | 0.50 |
| Overall | 1657 | 34 (3) | 22 (5) | 0.04 | 900 | 473 (75) | 211 (78) | 0.26 |
*Cases that were definitely and possibly related to the EUS procedure were included.
†Limited to EUS-FNA procedures only.
‡1: July to September, 2: October to December, 3: January to March, 4: April to June.
Factors associated with endoscopic ultrasound related adverse events risk, multivariate regression analysis*
| Training Period |
|
|
|
|---|---|---|---|
| First quartile† |
|
|
|
| EUS indication: pancreatic solid lesion | 0.75 (0.22–2.57) | 0.65 | |
| Same-day ERCP | 1.14 (0.12–10.49) | 0.91 | |
| FNA performed | 4.07 (1.14–8.65) | 0.03 | |
| Overall | Fellow present during procedure | 1.53 (0.87–2.68) | 0.14 |
| EUS indication: pancreatic solid lesion | 1.13 (0.60–2.11) | 0.70 | |
| Same-day ERCP | 2.84 (1.28–6.30) | 0.01 | |
| FNA performed | 2.04 (1.08–3.86) | 0.03 |
*Cases that were definitely- and possibly-related to the EUS procedure were included.
†July to September.
OR: odds ratio